Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H21N3O2 |
| Molecular Weight | 323.3889 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC(CC1)=C2C3=NC=C(N3CCC4=C2C=CC=C4)C(O)=O
InChI
InChIKey=HGWYFQCFNPVJKM-UHFFFAOYSA-N
InChI=1S/C19H21N3O2/c1-21-9-6-14(7-10-21)17-15-5-3-2-4-13(15)8-11-22-16(19(23)24)12-20-18(17)22/h2-5,12H,6-11H2,1H3,(H,23,24)
| Molecular Formula | C19H21N3O2 |
| Molecular Weight | 323.3889 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:48:45 UTC 2023
by
admin
on
Sat Dec 16 08:48:45 UTC 2023
|
| Record UNII |
T50E484899
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40598456
Created by
admin on Sat Dec 16 08:48:45 UTC 2023 , Edited by admin on Sat Dec 16 08:48:45 UTC 2023
|
PRIMARY | |||
|
19371526
Created by
admin on Sat Dec 16 08:48:45 UTC 2023 , Edited by admin on Sat Dec 16 08:48:45 UTC 2023
|
PRIMARY | |||
|
147083-93-0
Created by
admin on Sat Dec 16 08:48:45 UTC 2023 , Edited by admin on Sat Dec 16 08:48:45 UTC 2023
|
PRIMARY | |||
|
T50E484899
Created by
admin on Sat Dec 16 08:48:45 UTC 2023 , Edited by admin on Sat Dec 16 08:48:45 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
by one or more cytosolic enzymes
MAJOR
PLASMA
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
topical ocular administration |
|
||
| Tmax | PHARMACOKINETIC |
|
bilateral topical ocular administration of 0.25% alcaftadine ophthalmic solution |
|
||